Evidence map›Paper›PMID 41809059›Full record

ArticleInternational journal of particle therapy2026

Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma.

Cecilia Jiang, Travis Hoover, Jonathan Baron, Xiaoyan Han, Bolin Li, Yin Gao, Michele Kim, Harper Hubbeling, Elise A Chong, Jordan Carter and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cecilia JiangDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Travis HooverDepartment of Radiation Oncology, University of Maryland, Baltimore, MD, USA.
Jonathan BaronDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Xiaoyan HanDepartment of Biostatics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bolin LiDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Yin GaoDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Michele KimDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Harper HubbelingDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Elise A ChongDepartment of Medical Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Jordan CarterDepartment of Medical Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Jakub SvobodaDepartment of Medical Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Stephen J SchusterDepartment of Medical Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Daniel J LandsburgDepartment of Medical Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Sunita D NastaDepartment of Medical Oncology, University of Pennsylvania, Philadelphia, PA, USA.
John PlastarasDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Michael LaRiviereDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: The role of proton radiation (PT) for infradiaphragmatic targets in lymphoma patients is unknown. We report on radiation planning details, doses achieved to organs at risk (OARs), and outcomes for this population. Patient/material and methods: This is a single-institution retrospective study of patients with biopsy-proven lymphoma who received PT to infradiaphragmatic targets between 2011 and 2022. Comparison photon plans were generated for all patients. Toxicity was reported using CTCAE version 5.0. Dosimetric and clinical factors associated with toxicity and oncologic outcomes were assessed via Cox regression, while the paired Results: 38 patients comprising 40 PT courses were included. Median follow-up was 48 months. Top diagnoses were DLBCL (58%) and Hodgkin lymphoma (16%). 28% of PT courses had direct overlap with prior radiation and 20% were palliative. Median dose was 30.6 Gy over 17 fractions to locations including the spine/paraspinal region (30%), retroperitoneum (28%), and pelvis (22%). There were no acute G3+ toxicities. Among patients treated with curative intent, 44% experienced progression of disease (POD), mostly distant. 5/38 patients had a second malignancy after PT. Among the photon comparison plans, PT significantly decreased doses to the kidneys (mean and V5), small/large bowel (V5, V15), and numerous other abdominopelvic organ metrics. Large bowel V30 Gy was higher with PT (12.4 vs. 7.6 cc, p = p = .007). Interpretation: PT is well-tolerated and leads to excellent outcomes. PT can significantly reduce doses to key abdominopelvic OARs compared to photons.

Indexed as

LymphomaNeoplasmsProtonsRadiation

Identifiers

PMID41809059
PMCPMC12969308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.